Moderna, a US biotechnology company, which is also in contention in developing a COVID-19 vaccine, said that its candidate triggered similar immune response when tested on a small set of older patients seen in younger people during trials.
The claims came in light of an early phase trial of their vaccine on 20 people who were above the age of 56. The outcome was promising being equally effective on older population as the young adults. The elderly people are more vulnerable to COVID-19 with a higher fatality rate.
No severe effects were reported during the trial as the vaccine was well tolerated by the subjects. The side-effects reported by the patients like fatigue, pain, headaches were normal with anyone and vaccine. Two days after the vaccine was administered those minor side-effects also subsided.
India, on the other hand has permitted the trial of the Oxford University vaccine, the trial for which has already started on Wednesday. The first shots were given to six volunteers at Pune’s Bharati Vidyapeeth medical college and hospital.
Developed in collaboration with AstraZeneca, this vaccine is considered to be the most promising so far. It is undergoing phase-3 trials in some other countries as well.
Serum Institute of India in Pune has signed an agreement with AstraZeneca to mass-produce and market this vaccine in India. Both phase-2 and phase-3 trials would take place in India.
Anthony Fauci—a top US expert, andthe topmost authority on infectious diseases and the current epidemic, has warned against granting emergency use authorisations to novel Coronavirus vaccines. He has advised against allowing its use before all the necessary tests are completed. “The one thing that you would not want to see with a vaccine is getting an EUA before you have a signal of efficacy… One of the potential dangers, if you prematurely let a vaccine out, is that it would make it difficult, if not impossible, for other vaccines to enroll people in their trials,” said Fauci in Moderna, a US biotechnology company, which is also in contention while developing a COVID-19 vaccine, said that its candidate triggered a similar immune response when tested on a small set of older patients seen in younger people during trials.